Clinical trials: Gemcitabine
Metastatic Cancer Pancreas
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the…
- Trial name
- NCT02109445
- Testing
- PF-03084014, Gemcitabine, Nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pfizer
Breast Cancer
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
- Trial name
- NCT00320541
- Testing
- gemcitabine, paclitaxel, bevacizumab
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Triple Negative Breast Cancer, PD-L1 Positive
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with…
- Trial name
- ASCENT-04 (NCT05382286)
- Testing
- Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel
- Where
- 504 sites in United States, Argentina and 26 more
- Volunteers
- 443 people
- Sponsor
- Gilead Sciences
Solid Tumors
Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies
This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety, tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in…
- Trial name
- NCT00413686
- Testing
- AZD7762, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Breast Neoplasms
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer. Several studies have activity in patients of multiple lines of therapy, including patients that have been…
- Trial name
- NCT00191672
- Testing
- Gemcitabine, Paclitaxel, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer, Pancreatic Cancer
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT05919537
- Testing
- HMBD-001, Docetaxel, Nab-paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 68 people
- Sponsor
- Hummingbird Bioscience
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell…
- Trial name
- ZUMA-7 (NCT03391466)
- Testing
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 359 people
- Sponsor
- Kite, A Gilead Company
Soft Tissue Sarcoma
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
- Trial name
- NCT05712694
- Testing
- ADI PEG20
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 218 people
- Sponsor
- Polaris Group
Pancreatic Cancer
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
This single arm study will assess the efficacy and safety of Tarceva + gemcitabine in patients with locally advanced, unresectable or metastatic pancreatic cancer.
- Trial name
- NCT00642733
- Testing
- erlotinib [Tarceva], gemcitabine
- Where
- 2 sites in Mexico
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This open label, 2-part study will evaluate the safety and efficacy of RO5083945 in combination with standard chemotherapy in patients with advanced or recurrent non-small cell lung cancer who have not received prior…
- Trial name
- NCT01185847
- Testing
- RO5083945, cisplatin, gemcitabine
- Where
- 32 sites in Belgium, France and 5 more
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Neoplasms
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel combined with gemcitabine in Chinese patients with metastatic pancreatic cancer.
- Trial name
- PANC-001 (NCT02017015)
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 15 sites in China
- Volunteers
- 83 people
- Sponsor
- Celgene
Neoplasms, Breast
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
- Trial name
- NCT00790816
- Testing
- Lapatinib in combination with an anti-cancer agent, Lapatinib, Lapatinib in combination with an anti-cancer agent as specified by parent protocol
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.
HLX07 is a new anti-EGFR monoclonal antibody (mAb) with improved glycosylation pattern.In pre-clinical efficacy studies, HLX-07 is either equivalent or more potent than cetuximab in multiple cancer models without increased…
- Trial name
- HLX07Ib/II (NCT03577704)
- Testing
- HLX07+Gemcitabine+Cisplatin, HLX07+Paclitaxel+Carboplatin, HLX07+mFOLFOX6
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai Henlius Biotech
Lymphoma, B-Cell
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based…
- Trial name
- NCT04882163
- Testing
- CC-220, Polatuzumab vedotin, Rituximab
- Where
- 27 sites in United States, Austria and 6 more
- Sponsor
- Celgene
Advance Solid Tumors
Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors
Primary Objective: To determine a dose of SAR240550 to be further studied in combination with chemotherapy regimens Secondary Objectives: To determine the dose limiting toxicity (DLT) of SAR240550 and SAR240550 in combination…
- Trial name
- NCT01213381
- Testing
- Iniparib (SAR240550 - BSI-201), Gemcitabine, Carboplatin
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Sanofi
Classical Hodgkin Lymphoma
Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
This is an open-label, multicenter, randomized, phase3 trial to evaluate the efficacy of Camrelizumab in patients with relapsed or refractory classic Hodgkin's lymphoma.
- Trial name
- NCT04342936
- Testing
- Camrelizumab, Investigator's choice of Chemotherapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diffuse Large B-cell Lymphoma
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in…
- Trial name
- DALY 2-EU (NCT04844866)
- Testing
- MB-CART2019.1, Standard of Care
- Where
- 51 sites in Austria, Belgium and 12 more
- Volunteers
- 213 people
- Sponsor
- Miltenyi Biomedicine GmbH
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Triple Negative Breast Neoplasms
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative…
- Trial name
- NCT04191135
- Testing
- Pembrolizumab, Olaparib, Carboplatin
- Where
- 122 sites in United States, Canada and 13 more
- Volunteers
- 462 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.